D
INmune Bio, Inc. INMB
$7.32 $0.010.14% NASDAQ
Recommendation
Prev Close
$7.32
Volume
174,672
Avg Vol (90D)
338,604
Market Cap
$167.85M
Dividend & Yield
--
52-Week Range
$4.32 - $12.72
P/E (TTM)
--
EPS (TTM)
-$2.13
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
INmune Bio (INMB, $7.32) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 17, 2025
4/18/2025 - Tickeron - Technical Analysis
Inmune Bio Secures Favorable Patentability Opinion for CORDStrom
4/16/2025 - TipRanks Financial Blog
INmune Bio (INMB) Advances with Positive Patent Opinion for CORDStrom INMB Stock News
4/16/2025 - GuruFocus
INmune Bio receives favorable patentability opinion for CORDStrom platform
4/16/2025 - The Fly
INmune Bio Receives Favorable Patentability Opinion for CORDStrom Platform Technology
4/16/2025 - Globe Newswire
INmune Bio, CGT Catapult to set up manufacturing for cell therapy platforms
4/15/2025 - Pharmaceutical Business Review
INmune Bio (INMB) Partners to Enhance Cell Therapy Production
4/14/2025 - GuruFocus
INmune Bio partners with Cell and Gene Therapy Catapult
4/14/2025 - Seeking Alpha - Healthcare
INmune Bio (INMB) Partners with CGT Catapult for Large-Scale Cell Therapy Manufacturing INMB ...
4/14/2025 - GuruFocus
INmune Bio partners with Cell, Gene Therapy Catapult to scale up CORDStrom
4/14/2025 - The Fly
INmune Bio Partners with Cell and Gene Therapy Catapult to Scale Up CORDStrom Manufacturing for Commercial Readiness
4/14/2025 - Globe Newswire
INmune Bio (INMB, $7.3) Stochastic Oscillator left the oversold zone on April 07, 2025
4/8/2025 - Tickeron - Stocks
INmune Bio, Inc. (NASDAQ:INMB) Given Consensus Rating of "Buy" by Brokerages
4/6/2025 - MarketBeat
INmune Bio (INMB, $8.07) entered Downtrend as Momentum indicator drops below 0 level on Apr 02, 2025
4/3/2025 - Tickeron - Stocks
INmune Bio presents baseline demographics of participants in MINDFuL study
4/1/2025 - TipRanks Financial Blog
INmune Bio presents baseline demographics of participants in MINDFuL study
4/1/2025 - The Fly
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the ...
4/1/2025 - GuruFocus
INmune Bio Inc. Presents Baseline Demographics and Disease Profiles of Participants in the MINDFuL Phase II Study
4/1/2025 - Globe Newswire
Raymond James Financial Inc. Takes Position in INmune Bio, Inc. (NASDAQ:INMB)
3/31/2025 - MarketBeat
INmune Bio (NASDAQ:INMB) Posts Earnings Results
3/29/2025 - MarketBeat
INmune Bio (INMB, $7.52) Stochastic Oscillator left the oversold zone on March 28, 2025
3/29/2025 - Tickeron - Technical Analysis
INmune Bio's Earnings Call: Key Insights and Future Prospects
3/29/2025 - TipRanks Financial Blog
INmune Bio (INMB) Eyes Landmark Developments in 2024 Amid Rising Financial Commitments
3/28/2025 - GuruFocus
INmune Bio (INMB, $7.41) Moving Average Convergence Divergence (MACD) Histogram turned negative on March 27, 2025
3/28/2025 - Tickeron - Technical Analysis
INmune Bio (INMB, $7.41) Aroon Indicator entered a Downtrend on March 27, 2025.
3/28/2025 - Tickeron - Technical Analysis
Income Statement
Total Revenue (TTM)
$14.00K
EBITDA (TTM)
--
EBIT (TTM)
-$42.64M
Net Income (TTM)
-$42.08M
Balance Sheet
Total Assets (Q)
$39.56M
Total Debt (Q)
$384.00K
Total Liabilities (Q)
$7.47M
Book Value Per Share (Q)
$1.44
Cash Flow
Cash from Operations (TTM)
-$33.36M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$18.21M
Net Change in Cash (TTM)
-$14.93M
Filings
Filing Date
Thursday, March 27, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.63
7-Day Total Return
-4.06%
30-Day Total Return
-8.73%
60-Day Total Return
-7.11%
90-Day Total Return
49.39%
Year to Date Total Return
48.48%
1-Year Total Return
-16.82%
2-Year Total Return
-9.63%
3-Year Total Return
-2.14%
5-Year Total Return
54.76%
52-week Low
Dec 20, 2024 - $4.32
52-week High
Apr 30, 2024 - $12.72
Valuation
Market Cap
$167.85M - Micro Cap
Enterprise Value
$147.31M
Price/Sales (TTM)
12,200.00
Price/Book (Q)
5.08
Dividends and Shares
Shares Outstanding
22.25M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.inmunebio.com
Phone Number
858 964 3720
Address
225 NE Mizner Blvd.
Boca Raton, FL 33432
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and... more
NASDAQ 04/17/2025 4:00PM Eastern Quotes delayed